Ligands for Programmed Cell Death 1 Gene in Patients with Systemic Lupus Erythematosus
Overview
Authors
Affiliations
Objective: To investigate the role of ligands for programmed cell death 1 (PD-L) in the pathogenesis of systemic lupus erythematosus (SLE).
Methods: One hundred sixty-four patients with SLE and 160 healthy controls were enrolled in our study. The PD-L1 and PD-L2 polymorphisms were determined by polymerase chain reaction (PCR)/direct sequencing or restriction fragment length polymorphism (RFLP)-PCR.
Results: The genotype distributions of PD-L2 47103 C/T polymorphisms in patients with SLE were significantly different from those of the controls (p = 0.003). The genotype frequency of PD-L2 47103 T/T, in comparison with 47103 C/C, was significantly increased in patients with SLE when compared with that of the controls (odds ratio 2.5, 95% confidence interval 1.4-4.4, p = 0.001). A similar finding could also be found in the allele frequency of PD-L2 47103 T (SLE vs control, OR 1.7, 95% CI 1.3-2.4, p = 0.001). There were no significant differences in the genotype and allele frequencies of PD-L1 polymorphisms between the patients and controls.
Conclusion: PD-L2 47103 T may be associated with susceptibility to SLE in Taiwan.
Tang Y, Xu W, Fu L, Liu X, Huang A Clin Rheumatol. 2023; 43(1):489-499.
PMID: 37688767 DOI: 10.1007/s10067-023-06765-8.
Wang B, Chen C, Liu X, Zhou S, Xu T, Wu M Front Immunol. 2023; 14:1111005.
PMID: 36969198 PMC: 10030866. DOI: 10.3389/fimmu.2023.1111005.
Association of a Gene Polymorphism with Chronic Lymphatic Filariasis in a South Indian Cohort.
Venugopal G, ORegan N, Babu S, Schumann R, Srikantam A, Merle R Am J Trop Med Hyg. 2018; 100(2):344-350.
PMID: 30594267 PMC: 6367610. DOI: 10.4269/ajtmh.18-0731.
Targeting the programmed cell death-1 pathway in rheumatoid arthritis.
Sandigursky S, Silverman G, Mor A Autoimmun Rev. 2017; 16(8):767-773.
PMID: 28572054 PMC: 5596871. DOI: 10.1016/j.autrev.2017.05.025.
Meta-analysis of programmed cell death 1 polymorphisms with systemic lupus erythematosus risk.
Gao J, Gai N, Wang L, Liu K, Liu X, Wei L Oncotarget. 2017; 8(22):36885-36897.
PMID: 28415570 PMC: 5482706. DOI: 10.18632/oncotarget.16378.